组蛋白去乙酰化酶6抑制利用LKB1突变、KRAS驱动非小细胞肺癌的选择性代谢脆弱性
研究利用小鼠自体肿瘤来源的KRAS/LKB1(KL)与KRAS/TP53突变细胞系,比较基线及HDAC6抑制后的代谢表型,并在体外和体内评估HDAC6抑制对癌细胞与肿瘤生长的影响。KL突变细胞基线氧化还原敏感辅因子水平降低,对ACY-1215更敏感且缓冲氧化应激能力减弱;联合谷氨酰胺酶抑制在KL肺癌模型中增强细胞杀伤和抗肿瘤疗效。作者提出HDAC6抑制利用KL非小细胞肺癌代偿糖酵解受损能力下降的治疗窗,为KRAS突变伴LKB1共突变非小细胞肺癌提名新策略。
要点
- KL突变细胞基线氧化还原敏感辅因子水平降低,对HDAC6抑制剂ACY-1215更敏感。
- KL突变细胞增加代偿代谢和缓冲氧化应激的能力减弱。
- 谷氨酰胺酶抑制联合HDAC6抑制在KL肺癌模型中增强细胞杀伤和抗肿瘤疗效。
核心结论
- KL突变肿瘤代谢储备降低,HDAC6抑制基于代偿糖酵解受损能力下降利用KL非小细胞肺癌的治疗窗,为KRAS突变伴LKB1共突变非小细胞肺癌提名新策略。
研究设计与样本
- 使用携带KRAS/LKB1(KL)和KRAS/TP53突变基因型的小鼠自体肿瘤来源细胞系,以控制人模型中混杂的胚系和体细胞突变。
- 表征基线及HDAC6抑制后的代谢表型,并在体外测量HDAC6抑制对癌细胞生长的影响、在体内测量对肿瘤生长的影响。
主要发现
- KL突变细胞基线氧化还原敏感辅因子水平降低。
- KL突变细胞对药理HDAC6抑制(ACY-1215)的敏感性增加,且增加代偿代谢和缓冲氧化应激的能力减弱。
- 在KL肺癌模型中,谷氨酰胺酶抑制在体外和体内增强细胞杀伤和抗肿瘤疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In KRAS-mutant NSCLC, co-occurring alterations in LKB1 confer a negative prognosis compared with other mutations such as TP53. LKB1 is a tumor suppressor that coordinates several signaling pathways in response to energetic stress. Our recent work on pharmacologic and genetic inhibition of histone deacetylase 6 (HDAC6) revealed the impaired activity of numerous enzymes involved in glycolysis. On the basis of these previous findings, we explored the therapeutic window for HDAC6 inhibition in metabolically-active KRAS-mutant lung tumors. METHODS: Using cell lines derived from mouse autochthonous tumors bearing the KRAS/LKB1 (KL) and KRAS/TP53 mutant genotypes to control for confounding germline and somatic mutations in human models, we characterize the metabolic phenotypes at baseline and in response to HDAC6 inhibition. The impact of HDAC6 inhibition was measured on cancer cell growth in vitro and on tumor growth in vivo. RESULTS: Surprisingly, KL-mutant cells revealed reduced levels of redox-sensitive cofactors at baseline. This is associated with increased sensitivity to pharmacologic HDAC6 inhibition with ACY-1215 and blunted ability to increase compensatory metabolism and buffer oxidative stress. Seeking synergistic metabolic combination treatments, we found enhanced cell killing and antitumor efficacy with glutaminase inhibition in KL lung cancer models in vitro and in vivo. CONCLUSIONS: Exploring the differential metabolism of KL and KRAS/TP53-mutant NSCLC, we identified decreased metabolic reserve in KL-mutant tumors. HDAC6 inhibition exploited a therapeutic window in KL NSCLC on the basis of a diminished ability to compensate for impaired glycolysis, nominating a novel strategy for the treatment of KRAS-mutant NSCLC with co-occurring LKB1 mutations.
引用
- Zhang H, Nabel CS, Li D, et al. Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC. J Thorac Oncol. 2023. PMID: 36958689. doi:10.1016/j.jtho.2023.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。